<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">Virol J</span><span class="iso-abbrev" title="iso-abbrev">Virol. J</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Virology Journal</span></div><span class="issn-epub" tagx="issn" title="issn-epub">1743-422X</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">BioMed Central</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">London</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7338124">7338124</a></span><span class="publisher-id" title="publisher-id">1375</span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1186/s12985-020-01375-1">10.1186/s12985-020-01375-1</a></span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Heui Man</span></span><a href="#Aff1" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">Namjoo</span></span><a href="#Aff1" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Mi-Seon</span></span><a href="#Aff1" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kang</span><span class="given-names" tagx="given-names" title="given-names">Chun</span></span><a href="#Aff1" /></span><span class="contrib" title="contrib"><span class="contrib-id" tagx="contrib-id" title="contrib-id">http://orcid.org/0000-0003-4562-5533</span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chung</span><span class="given-names" tagx="given-names" title="given-names">Yoon-Seok</span></span><span class="address" title="address"><span class="email" tagx="email" title="email">rollstone93@korea.kr</span></span><a href="#Aff1" /></span><span class="citation_author_institution" id="Aff1">[], <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">grid.418967.5</span><span class="institution-id" title="institution-id">0000 0004 1763 8617</span><span class="institution" title="institution">Division of Viral Diseases, Center for Laboratory Control of Infectious Diseases, </span><span class="institution" title="institution">Korea Centers for Disease Control and Prevention, </span></div></span></div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-7-7</span></span><span class="pub-date-pmc-release" title="pub-date-pmc-release">pmc-release: <span>2020-7-7</span></span><span class="pub-date-collection" title="pub-date-collection">collection: <span>2020</span></span><span class="volume" tagx="volume" title="volume">17</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">94</span><span class="history" title="history"><span class="received" title="received">received: 2020-3-18</span><span class="accepted" title="accepted">accepted: 2020-6-30</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p"><b>Open Access</b>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</span></span></div> <div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="background" title="sec"> <div class="title" tagx="title" title="title">
Background</div> <p id="Par1">The emergence of influenza viruses resistant to anti-influenza drugs is a threat to global public health. The Korea Centers for Disease Control and Prevention operates the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS) to monitor epidemics of influenza and Severe Acute Respiratory Infection (SARI) to identify mutated influenza viruses affecting drug resistance, pathogenesis, and transmission.</p> </div> <div class="methods" title="sec"> <div class="title" tagx="title" title="title">
Methods</div> <p id="Par2">Oropharyngeal swab samples were collected from KINRESS and SARI during the 2018â€"2019 season. The specimens confirmed influenza virus using real-time RT-PCR on inoculated MDCK cells. HA and NA sequences of the influenza viruses were analyzed for phylogeny and mutations. Neuraminidase inhibition and hemagglutination inhibition assays were utilized to characterize the isolates.</p> </div> <div class="results" title="sec"> <div class="title" tagx="title" title="title">
Results</div> <p id="Par3">Two A(H1N1)pdm09 isolates harboring an H275Y substitution in the neuraminidase sequence were detected in patients with acute hematologic cancer. They had prolonged respiratory symptoms, with the virus present in the respiratory tract despite oseltamivir and peramivir treatment. Through the neuraminidase inhibition assay, both viruses were found to be resistant to oseltamivir and peramivir, but not to zanamivir. Although hemagglutinin and neuraminidase phylogenetic analyses suggested that the 2 A(H1N1)pdm09 isolates were not identical, their antigenicity was similar to that of the 2018â€"19 influenza vaccine virus.</p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="Par4">Our data indicate the utility of monitoring influenza-infected immunocompromised patients in general hospitals for the early detection of emerging neuraminidase inhibitor-resistant viruses and maintaining continuous laboratory surveillance of patients with influenza-like illness in sentinel clinics to monitor the spread of such new variants. Finally, characterization of the virus can inform the risk assessment for future epidemics and pandemics caused by drug-resistant influenza viruses.</p> </div> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Influenza virus</div> <div class="kwd" title="kwd">
Drug resistance</div> <div class="kwd" title="kwd">
H275Y</div> <div class="kwd" title="kwd">
Immunocompromised patients</div> </div> <div class="funding-group" title="funding-group"> <div class="funding" title="funding">
Funding</div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution-id" title="institution-id">http://dx.doi.org/10.13039/501100003669</span><span class="institution" title="institution">Korea Centers for Disease Control and Prevention</span></div> </div><span class="award-id" tagx="award-id" title="award-id">4834-303</span><span class="principal-award-recipient" title="principal-award-recipient"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Heui Man</span></span></span></div> </div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="issue-copyright-statement" value="Â© The Author(s) 2020" /> </div> </div> </div> <div class="body" title="body"> <div class="background" title="sec"> <div class="title" tagx="title" title="title">
Background</div> <p id="Par15">Neuraminidase inhibitors (NAIs) are globally utilized for the treatment and prevention of influenza types A and B infection [<a href="#CR1">1</a>], which are stockpiled by some countries, including the Republic of Korea, against unexpected pandemics. NAIs suppress the action of neuraminidase (NA) on the surface of the virus to prevent the spread of progeny virus from infected cells [<a href="#CR2">2</a>]. Oseltamivir and peramivir, the most commonly used drugs for patients with influenza-like illnesses in the Republic of Korea, help to relieve clinical symptoms within 2 days of symptom manifestation and shorten the virus-release period in the respiratory tract [<a href="#CR1">1</a>]. Baloxavir, a cap-dependent endonuclease inhibitor, was also recently licensed in the United States, following Japan [<a href="#CR3">3</a>]. However, since most recently detected type A influenza viruses harbor the resistance variation S31N in the matrix gene, the M2 proton-channel blockers amantadine and rimantadine are no longer clinically applied [<a href="#CR4">4</a>].</p> <p id="Par16">The Korea Centers for Diseases Control and Prevention (KCDC) has operated the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS) to monitor epidemic features of influenza viruses and analyze virus characteristics, including drug resistance, since 2000. The KCDC carries out diagnostic testing for influenza viruses in respiratory specimens requested by general hospitals as a national standard laboratory. If a drug resistance mutation is found in the NA gene, the KINRESS attempts to isolate the virus and perform phenotypic analysis (NA inhibition assay). The typical drug-resistance substitutions in NA include H275Y, E119D/G, and Q136R for A(H1N1)pdm09; E119V, D151G/V/D, R224K, E276D, R292K, and N294S for A (H3N2); and G104E, E117A/D, H134Y, and R150K for B virus [<a href="#CR5">5</a>], although additional single and combination mutations may also result in NAI drug resistance (World Health Organization (WHO)) [<a href="#CR6">6</a>]. Flusurver provides genetic analysis tools for screening drug-resistance and variant mutations to facilitate genetic characterization of viruses [<a href="#CR7">7</a>]. Fluorescence-based NA inhibition assays using the MUNANA substrate have been conducted to confirm drug-resistant virus phenotyping [<a href="#CR8">8</a>]. NAI-resistant viruses were identified in cases in which influenza virus was continuously detected following NAI treatment of hospitalized, immunosuppressed patients, rather than in clinical outpatients [<a href="#CR9">9</a>]. Here, drug-resistant A(H1N1)pdm09 viruses were detected via the KINRESS in patients with acute hematologic cancer not exhibiting recovery despite oseltamivir and peramivir administration; these were characterized genetically and antigenically following isolation.</p> </div> <div class="methods" title="sec"> <div class="title" tagx="title" title="title">
Methods</div> <div class="clinicalspecimencollection" title="sec"> <div class="title" tagx="title" title="title">
Clinical specimen collection</div> <p id="Par17">Oropharyngeal swab samples were collected from patients with influenza-like illness through the KINRESS and processed in the national standard laboratory. Swabs were stored in Viral Transport Media (BD, San Jose, CA, USA) until further analysis.</p> </div> <div class="viralrnaextraction" title="sec"> <div class="title" tagx="title" title="title">
Viral RNA extraction</div> <p id="Par18">Viral RNA was extracted from 140â€‰Î¼L of sample medium using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturerâ€™s instructions.</p> </div> <div class="one-stepmultiplexreal-timereversetranscription-polymerasechainreaction(rt-pcr)" title="sec"> <div class="title" tagx="title" title="title">
One-step multiplex real-time reverse transcription-polymerase chain reaction (RT-PCR)</div> <p id="Par19">RT-PCR was carried out using the Agpath ID One-step RT-PCR system (Applied Biosystems, Foster City, CA, USA) [<a href="#CR10">10</a>]. TableÂ <a href="#Tab1">1</a> lists multiplex (A/B/IPC and H1/H3/IPC) primer and Taq-Man probe sets. The 20-Î¼L reaction mixture contained 5â€‰Î¼L of RNA template, 590â€‰nM primers, 140â€‰nM probe, 10â€‰Î¼L of 2Ã— reaction buffer, 0.8â€‰Î¼L of enzyme mixture, and RNase-free water. RT-PCR was performed on the ABI 7500Fast instrument (Applied Biosystems) with thermocycler conditions for reverse transcription (50â€‰Â°C, 30â€‰min), hot start DNA Taq polymerase activation (95â€‰Â°C, 10â€‰min), followed by 40â€‰cycles of denaturation (95â€‰Â°C, 15â€‰s) and annealing/extension (55â€‰Â°C, 30â€‰s). Data acquisition and analysis of the real-time PCR assay were performed using SDS software Version 1.4 (Applied Biosystems). <div class="table-wrap_UNKNOWN" id="Tab1"><span class="label" tagx="label" title="label">Table 1</span> </div></p><p>Primer and probe sequence information to detect influenza virus type (A/B) and subtype (H1/H3)</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Type/Subtype</th> <th>Primer/probe</th> <th>Sequence (5â€²â€"3â€²)</th> <th>Target (bp)</th> </tr> </thead> <tbody> <tr> <td rowspan="3">A</td> <td>Forward</td> <td>AATCCTGTCACCTCTGACTAAGG</td> <td rowspan="3"> <p>Matrix</p> <p>(98)</p> </td> </tr> <tr> <td>Reverse</td> <td>CATTYTGGACAAAKCGTCTACG</td> </tr> <tr> <td>Probe</td> <td>FAM-TGCAGTCCTCGCTCAC-MGBNFQ</td> </tr> <tr> <td rowspan="3">B</td> <td>Forward</td> <td>GAATGCTGTCAATGAATATTGAGGG</td> <td rowspan="3"> <p>Nucleoprotein</p> <p>(77)</p> </td> </tr> <tr> <td>Reverse</td> <td>CATTGAGTCATTCATCATCTTGAGTAGAT</td> </tr> <tr> <td>Probe</td> <td>VIC-TCCTTTGACATCTGCAT-MGBNFQ</td> </tr> <tr> <td rowspan="3">H1</td> <td>Forward</td> <td>AACAATTCAACAGACACTGTAGACACAGT</td> <td rowspan="3">Hemagglutinin (144)</td> </tr> <tr> <td>Reverse</td> <td>GGGCTACCCCTCTTAGTTTRCATAGTTT</td> </tr> <tr> <td>Probe</td> <td>FAM- ATGTAACAGTAACACACTCTGT-MGBNFQ</td> </tr> <tr> <td rowspan="3">H3</td> <td>Forward</td> <td>GGAATGGTTTGTCATTGGGAAT</td> <td rowspan="3">Hemagglutinin (95)</td> </tr> <tr> <td>Reverse</td> <td>AAGCTCAATAATGAGRTCAGATGCA</td> </tr> <tr> <td>Probe</td> <td>VIC-CTTCCATTTGGAGTRATRCA-MGBNFQ</td> </tr> <tr> <td rowspan="3">IPC</td> <td>Forward</td> <td>AGATTTGGACCTGCGAGCG</td> <td rowspan="3"> <p><i>GAPDH</i></p> <p>(65)</p> </td> </tr> <tr> <td>Reverse</td> <td>GAGCGGCTGTCTCCACAAGT</td> </tr> <tr> <td>Probe</td> <td>Cy5-TTCTGACCTGAAGGCTCTGCGCG-BHQ</td> </tr> </tbody> </table>  <p /> </div> <div class="virusisolationinmdckcelllines" title="sec"> <div class="title" tagx="title" title="title">
Virus isolation in MDCK cell lines</div> <p id="Par20">Madin-Darby canine kidney (MDCK, American Type Culture Collection, Manassas, VA, USA) cells were seeded at 10<sup>5</sup>/mL in T25 flasks with Dulbeccoâ€™s modified Eagle medium (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (Hyclone) and 1% penicillinâ€"streptomycin (Sigma, St. Louis, MO, USA) in a final volume of 5â€‰mL and incubated at 37â€‰Â°C in a humidified atmosphere with 5% CO<sub>2</sub> for 48â€‰h. When the cells reached 90% confluence, the culture medium was discarded, and the cells were washed three times with warm phosphate-buffered saline. Then, 0.2â€‰mL of clinical specimen was added into a flask to allow the inoculum to adsorb (37â€‰Â°C, 60â€‰min). Medium (5â€‰mL) containing 2â€‰Î¼L/mL TPCK-trypsin was added to the flask. The culture was observed daily for cytopathic and morphological changes using an inverted light microscope. The culture supernatant was harvested when 75â€"100% of the infected cells showed cytopathic effect and stored at âˆ’â€‰70â€‰Â°C [<a href="#CR11">11</a>]. Finally, A/Korea/S0002/2019 and A/Korea/S0003/2019 A(H1N1)pdm09 viruses were isolated.</p> </div> <div class="hemagglutinin(ha)andneuraminidase(na)sequencing" title="sec"> <div class="title" tagx="title" title="title">
Hemagglutinin (HA) and neuraminidase (NA) sequencing</div> <p id="Par21">Viral RNA was extracted from oropharyngeal swab samples and their isolates using the QIAamp Viral RNA Mini Kit (Qiagen) according to the manufacturerâ€™s instructions. Reverse transcription was performed to obtain cDNA using the U12 primer, then the HA and NA genes were amplified with specific primers [<a href="#CR12">12</a>]. The PCR products were purified using the QIAquickâ"¢ PCR Purification Kit (Qiagen) according to the manufacturerâ€™s instructions and subjected to direct sequencing using the Big Dye Terminator V.3.0â€‰Cycle Sequencing Ready Reaction Kit (Applied Biosystems) together with primers for each PCR fragment (TableÂ <a href="#Tab2">2</a>) on the ABI 3130xl Genetic Analyzer automatic sequencer (Applied Biosystems). The nucleotide sequences were edited, assembled, and aligned using MEGA X 10.1 software (<a href="https://www.megasoftware.net/">https://www.megasoftware.net/</a>). The complete HA (GISAID: EPI1602907 and EPI1602905) and NA (GISAID: EPI1602908 and EPI1602906) sequences were obtained from the 2 A(H1N1)pdm09 viruses. <div class="table-wrap_UNKNOWN" id="Tab2"><span class="label" tagx="label" title="label">Table 2</span> </div></p><p>Sequencing primers for HA and NA of A(H1N1)pdm09 virus</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Primers (F/R)</th> <th>Gene (subtype)</th> <th>Locus</th> <th>Sequence (5â€²â€"3â€²)</th> </tr> </thead> <tbody> <tr> <td>A-uni-HA-1F</td> <td>HA</td> <td>1â€"28</td> <td>TATTCGTCTCAGGGAGCAAAAGCAGGGG</td> </tr> <tr> <td>HA-H1-345F</td> <td>HA (H1)</td> <td>345â€"365</td> <td>GGAACGTGTTACCCAGGAGAT</td> </tr> <tr> <td>HA-H1-680F</td> <td>HA (H1)</td> <td>680â€"701</td> <td>TCAAGCCGGAAATAGCAATAAG</td> </tr> <tr> <td>HA-H1-1137F</td> <td>HA (H1)</td> <td>1137â€"1156</td> <td>AGCCGACCTGAAGAGCACAC</td> </tr> <tr> <td>HA-H1-714R</td> <td>HA (H1)</td> <td>691â€"714</td> <td>CCTCACTTTGGGTCTTATTGCTAT</td> </tr> <tr> <td>HA-H1-1093R</td> <td>HA (H1)</td> <td>1072â€"1093</td> <td>CATCCATCTACCATCCCTGTCC</td> </tr> <tr> <td>HA-H1-1330R</td> <td>HA (H1)</td> <td>1309â€"1330</td> <td>GCATTGTAAGTCCAAATGTCCA</td> </tr> <tr> <td>A-uni-HA-1807R</td> <td>HA</td> <td>1773â€"1807</td> <td>ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT</td> </tr> <tr> <td>A-uni-NA-1F</td> <td>NA</td> <td>1â€"29</td> <td>TATTGGTCTCAGGGAGCAAAAGCAGGAGT</td> </tr> <tr> <td>H1-NA-324F</td> <td>NA (N1)</td> <td>324â€"345</td> <td>GGTTCCAAGGGGGATGTGTTTG</td> </tr> <tr> <td>H1-NA-744F</td> <td>NA (N1)</td> <td>744â€"766</td> <td>TGGACAGGCCTCATACAAGATCT</td> </tr> <tr> <td>H1-NA-645R</td> <td>NA (N1)</td> <td>622â€"645</td> <td>AGTGTCTGTTATTATTCCGTTGTA</td> </tr> <tr> <td>H1-NA-1010F</td> <td>NA (N1)</td> <td>985â€"1010</td> <td>CAGTATCGTCTAATGGAGCAAATGGA</td> </tr> <tr> <td>H1-NA-1057R</td> <td>NA (N1)</td> <td>1036â€"1057</td> <td>CTATCCAAACACCATTGCCGTA</td> </tr> <tr> <td>A-uni-NA-1442R</td> <td>NA</td> <td>1407â€"1442</td> <td>ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT</td> </tr> </tbody> </table>  <p /> </div> <div class="geneticcharacterization" title="sec"> <div class="title" tagx="title" title="title">
Genetic characterization</div> <p id="Par22">Genetic screening for drug resistance in the NA gene and mutational analysis of the HA and NA genes were conducted using Flusurver (<a href="https://flusurver.bii.a-star.edu.sg/">https://flusurver.bii.a-star.edu.sg/</a>), last updated on July 26, 2019. Phylogenies were reconstructed using the neighbor-joining method and bootstrapped 1000 times with MEGA X 10.1 using HA- or NA-aligned DNA sequences of the A(H1N1)pdm09 reference vaccine [<a href="#CR13">13</a>] and other isolates from the Republic of Korea.</p> </div> <div class="nainhibitionassay" title="sec"> <div class="title" tagx="title" title="title">
NA inhibition assay</div> <p id="Par23">A fluorescence-based neuraminidase inhibition assay was conducted using the NA-Fluorâ"¢ Influenza Neuraminidase Assay Kit (Applied Biosystems), according to the manufacturerâ€™s instructions. The susceptibility of influenza viruses to NAI was characterized using oseltamivir, zanamivir, and peramivir at concentrations that inhibited the NA activity by 50% (IC<sub>50</sub>) as described previously [<a href="#CR14">14</a>]. As defined by the WHO, influenza A viruses with normal, reduced, and highly reduced NA activity inhibition exhibit aâ€‰<div class="â€‰10-fold,_UNKNOWN">
50, respectively; the last are considered clinically resistant [<a href="#CR15">15</a>].</div></p> </div> <div class="hemagglutinationinhibition(hi)assay" title="sec"> <div class="title" tagx="title" title="title">
Hemagglutination inhibition (HI) assay</div> <p id="Par24">Assays were performed according to standard methods [<a href="#CR16">16</a>]. Four HA units/25â€‰Î¼L of A(H1N1)pdm09 virus were tested using 0.5% suspensions of turkey red blood cells. HI titers were reciprocals of the highest dilutions of sera that inhibited hemagglutination. Post-infection ferret antisera against 18â€"19 and 19â€"20 vaccine viruses were treated with receptor-destroying enzyme (Denka Seiken, Tokyo, Japan).</p> </div> </div> <div class="results" title="sec"> <div class="title" tagx="title" title="title">
Results</div> <div class="a(h1n1)pdm09detectionandisolationinimmunocompromisedpatients" title="sec"> <div class="title" tagx="title" title="title">
A(H1N1)pdm09 detection and isolation in immunocompromised patients</div> <p id="Par25">Influenza A virus was detected in oropharyngeal swab samples collected from patients with lymphoblastic leukemia (Patient A: female, 37â€‰years old) and relapsed lymphoma (Patient B: female, 38â€‰years old), with real-time RT-PCR Ct values of 28 and 29, respectively. A(H1N1)pdm09 viruses were identified by additional H1 subtype detection at respective Ct values of 28 and 29 (TableÂ <a href="#Tab3">3</a>). Plaques were observed within 48â€‰h following specimen inoculation in MDCK cells, with the harvested supernatant exhibiting an HA titer of 256. The isolates were named A/Korea/S0002/2019 and A/Korea/S0003/2019. <div class="table-wrap_UNKNOWN" id="Tab3"><span class="label" tagx="label" title="label">Table 3</span> </div></p><p>A(H1N1)pdm09 virus detection in immunocompromised patients by real-time RT-PCR</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th rowspan="2">Patient</th> <th colspan="5">Genetic detection using real-time RT-PCR</th> </tr> <tr> <th>IFV A</th> <th>IFV B</th> <th>A/H1</th> <th>A/H3</th> <th>IPC</th> </tr> </thead> <tbody> <tr> <td>A</td> <td char="." align="char">26.1</td> <td>UD<sup>*</sup></td> <td>25.4</td> <td>UD<sup>*</sup></td> <td>26.3/26.2</td> </tr> <tr> <td>B</td> <td char="." align="char">27.0</td> <td>UD<sup>*</sup></td> <td>25.8</td> <td>UD<sup>*</sup></td> <td>32.1/34.0</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p>UD<sup>*</sup>: undetected</p> </div>  <p /> </div> <div class="geneticcharacterization" title="sec"> <div class="title" tagx="title" title="title">
Genetic characterization</div> <div class="nageneticanalysisforscreeningdrugresistance,phylogeny,andvariation" title="sec"> <div class="title" tagx="title" title="title">
NA genetic analysis for screening drug resistance, phylogeny, and variation</div> <p id="Par26">The sequences of the NA gene from oropharyngeal swab samples and the isolated viruses from each patient were determined and were found to have no mutations resulting from adaptation to the cell culture conditions. The H275Y NA substitution (N1 numbering), associated with strong drug resistance, was observed in (GISAID: EPI1602908 and EPI1602906) of A(H1N1)pdm09 isolates from both immunocompromised patients. Other NA drug-resistance substitutions (V116A, I117V, Q136K, D151A, Y155H, R156K, D198V, I222V, R224K, Q226H, E227D, E277Q, R293K, N294S, E425G, and I436N) were not detected. The NA sequences of A/Korea/S0002/2019 and A/Korea/S0003/2019 most closely matched with those of A/Brisbane/02/2018 (98.5 and 98.3% amino-acid identity, respectively). The viruses could be distinguished in the phylogenetic tree (Fig.Â <a href="#Fig1">1</a>). A/Korea/S0002/2019 had six amino acid differences (T13I, Q51K, F74S, H275Y, D416N, and T452I) relative to A/Brisbane/02/2018 (TableÂ <a href="#Tab4">4</a>), while A/Korea/S0003/2019 had eight (T13I, I29M, P93S, I99V, H275Y, G298A, V321I, and V394I). Table <a href="#Tab4">4</a> shows the amino acid substitutions in NA compared with A/Brisbane/02/2018 and their reported effects. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 1</span></a></div>   <p>Phylogenetic tree of neuraminidase (NA) gene of drug resistant A(H1N1)pdm09. The H275Y mutated viruses (A/Korea/S0002/2019 and A/Korea/S0003/2019) were not identical in phylogenetic tree of NA. A/Korea/S0002/2019 harbored Q51K, F74S, T152I and D416N mutation and A/Korea/S0003/2019 harbored I29M, P93S, I99V, G298A, V321I and V394I mutation compared to A/Brisbane/02/2018</p>   </div> <div class="table-wrap_UNKNOWN" id="Tab4"><span class="label" tagx="label" title="label">Table 4</span> <p>NA genetic mutations compared with A/Brisbane/02/2018 (N1 numbering)</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Virus</th> <th>Amino acid identity with A/Brisbane/02/2018 (%)</th> <th>T13I</th> <th>I29M</th> <th>Q51K</th> <th>F74S</th> <th>P93S<sup>a,b</sup></th> <th>I99V<sup>b</sup></th> <th>H275Y<sup><b>c</b></sup></th> <th>G298A<sup>a</sup></th> <th>V321I<sup>a</sup></th> <th>V394I<sup>b</sup></th> <th>D416N<sup>a,b</sup></th> <th>T452I<sup>a,b,d</sup></th> </tr> </thead> <tbody> <tr> <td>A/Korea/S0003/2019</td> <td>98.3</td> <td>â—‹</td> <td>â—‹</td> <td /> <td /> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td /> <td /> </tr> <tr> <td>A/Korea/S0002/2019</td> <td>98.5</td> <td>â—‹</td> <td /> <td>â—‹</td> <td>â—‹</td> <td /> <td /> <td>â—‹</td> <td /> <td /> <td /> <td>â—‹</td> <td>â—‹</td> </tr> <tr> <td colspan="2">Frequency (%)</td> <td>99.79</td> <td>0.65</td> <td>18.14</td> <td>16.78</td> <td>0.34</td> <td>0.89</td> <td>0.58</td> <td>0.75</td> <td>1.13</td> <td>1.37</td> <td>36.25</td> <td>18.76</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p>â—‹ substitution of the amino acid indicated</p> <p><sup>a</sup>Binding small ligand</p> <p><sup>b</sup>viral oligomerization interfaces</p> <p><sup>c</sup>strong drug resistance</p> <p><sup>d</sup>binding host protein</p> </div> </div> <p /> </div> <div class="haphylogenyandvariation" title="sec"> <div class="title" tagx="title" title="title">
HA phylogeny and variation</div> <p id="Par27">In the HA phylogenetic tree, two viruses belonged to clade 6B.1A, including A/Brisbane/02/2018 and a virus similar to a 2018â€"2019 season-isolated A(H1N1)pdm09 in the Republic of Korea. A/Korea/S0002/2019 and A/Korea/S0003/2019 HA sequences best matched with those of A/Brisbane/02/2018 (98.6 and 98.9% amino-acid identity, respectively). The two viruses fell into different subclades according to discrepancies at residues 158, 202, 277, and 521. A/Korea/S0002/2019 belonged to subclade 6B.1A5 and A/Korea/S0003/2019 to subclade 6B.1A4 (Fig.Â <a href="#Fig2">2</a>). TableÂ <a href="#Tab5">5</a> shows the amino-acid substitutions in the HA gene compared with A/Brisbane/02/2018 and their reported effects. </p><div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Fig. 2</span></a></div>   <p>Phylogenetic tree of hemagglutinin (HA) gene of drug resistant A(H1N1)pdm09. A/Korea/S0002/2019 virus belonged to 6B.1A5 harboring T202I, N277D and K521R mutations compared to A/Brisbane/02/2018 and clustered with isolated viruses in 2019â€‰year, Republic of Korea (ROK), whereas A/Korea/S0003/2019 virus belonged to 6B.1A4 harboring A158E mutation and clustered with isolated viruses in previous year</p>   </div> <div class="table-wrap_UNKNOWN" id="Tab5"><span class="label" tagx="label" title="label">Table 5</span> <p>HA genetic variation compared with A/Brisbane/02/2018 (H1 numbering)</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th>Virus</th> <th>Amino acid identity with A/Brisbane/02/2018 (%)</th> <th>G62R<sup>a,b,c</sup></th> <th>N146D<sup>a,b,c</sup></th> <th>A158E <sup>a,b,c</sup></th> <th>T202I <sup>a,b,c</sup></th> <th>R240Q <sup>a,c,d</sup></th> <th>N277D<sup>b</sup></th> <th>A299P<sup>a,b</sup></th> <th>V315I<sup>a,b</sup></th> <th>K521<sup>b</sup></th> </tr> </thead> <tbody> <tr> <td>A/Korea/S0003/2019</td> <td>98.94</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td /> <td>â—‹</td> <td /> <td>â—‹</td> <td>â—‹</td> <td /> </tr> <tr> <td>A/Korea/S0002/2019</td> <td>98.59</td> <td>â—‹</td> <td>â—‹</td> <td /> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> <td>â—‹</td> </tr> <tr> <td colspan="2">Frequency (%)</td> <td>84.19</td> <td>17.76</td> <td>0.97</td> <td>19.77</td> <td>99.87</td> <td>29.46</td> <td>84.85</td> <td>85.38</td> <td>3.08</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <p>â—‹ substitution of the amino acid indicated</p> <p><sup>a</sup>Binding small ligand</p> <p><sup>b</sup>viral oligomerization interfaces</p> <p><sup>c</sup>antibody recognition sites</p> <p><sup>d</sup>host cell receptor binding</p> </div> </div> <p /> </div> </div> <div class="nainhibitionassay" title="sec"> <div class="title" tagx="title" title="title">
NA inhibition assay</div> <p id="Par28">A/Korea/S0003/2019 and A/Korea/S0002/2019 viruses exhibited significantly reduced inhibition by oseltamivir and peramivir with &amp;gt;â€‰100 IC<sub>50</sub> fold-changes relative to drug-sensitive virus, but were normally susceptible to zanamivir (TableÂ <a href="#Tab6">6</a>). However, every isolate collected from the KINRESS in 2018â€"2019 was susceptible to all three drugs. <div class="table-wrap_UNKNOWN" id="Tab6"><span class="label" tagx="label" title="label">Table 6</span> </div></p><p>Neuraminidase inhibition assay for A(H1N1)pdm09 viruses isolated in immunocompromised patients</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th rowspan="2">Virus</th> <th rowspan="2">Type (Subtype)</th> <th rowspan="2">Genotype</th> <th colspan="3">NAI resistance (IC<sub>50</sub> fold change)</th> </tr> <tr> <th>Oseltamivir</th> <th>Zanamivir</th> <th>Peramivir</th> </tr> </thead> <tbody> <tr> <td>A/Korea/S0003/2019</td> <td rowspan="2">A(H1N1)pdm09</td> <td>Variant (H275Y)</td> <td> <p>HRI</p> <p>179.33</p> </td> <td> <p>NI</p> <p>2.56</p> </td> <td> <p>HRI</p> <p>117.74</p> </td> </tr> <tr> <td>A/Korea/S0002/2019</td> <td>Variant (H275Y)</td> <td> <p>HRI</p> <p>221.58</p> </td> <td> <p>NI</p> <p>0.44</p> </td> <td> <p>HRI</p> <p>168.48</p> </td> </tr> <tr> <td rowspan="3">2018â€"2019 isolates</td> <td>A(H1N1)pdm09</td> <td>Wild</td> <td>0.1â€"1.2</td> <td>0.3â€"0.7</td> <td>0.1</td> </tr> <tr> <td>A(H3N2)</td> <td>Wild</td> <td>0.1â€"0.2</td> <td>0.4â€"0.8</td> <td>0.2â€"0.3</td> </tr> <tr> <td>B</td> <td>Wild</td> <td>9â€"16</td> <td>0.7â€"1.6</td> <td>0.3â€"0.4</td> </tr> </tbody> </table>  <p /> </div> <div class="antigeniccharacterization" title="sec"> <div class="title" tagx="title" title="title">
Antigenic characterization</div> <p id="Par29">The two viruses were well inhibited by antisera from ferrets immunized with A/Michigan/45/2015 and A/Brisbane/02/2018, which are northern-hemisphere influenza A(H1N1)pdm09 isolates collected in 2018â€"2019 and 2019â€"2020, respectively, with less than two-fold reduced HI titer relative to homologous virus (TableÂ <a href="#Tab7">7</a>). <div class="table-wrap_UNKNOWN" id="Tab7"><span class="label" tagx="label" title="label">Table 7</span> </div></p><p>Hemagglutinin inhibition assay</p>  <table frame="hsides" rules="groups"> <thead> <tr> <th rowspan="3">Virus</th> <th colspan="2">Hemagglutination inhibition titer</th> </tr> <tr> <th colspan="2">Post-infection ferret antisera</th> </tr> <tr> <th>A/Michigan/45/2015 Egg</th> <th>A/Brisbane/02/2018 Egg</th> </tr> </thead> <tbody> <tr> <td>A/Korea/S0003/2019 MDCK</td> <td>640</td> <td>640</td> </tr> <tr> <td>A/Korea/S0002/2019 MDCK</td> <td>320</td> <td>640</td> </tr> <tr> <td>A/Michigan/45/2015 MDCK</td> <td>1280</td> <td>640</td> </tr> <tr> <td>A/Brisbane/02/2018 MDCK</td> <td>640</td> <td>1280</td> </tr> </tbody> </table>  <p /> </div> </div> <div class="discussion" title="sec"> <div class="title" tagx="title" title="title">
Discussion</div> <p id="Par30">The NAI-resistant A(H1N1) virus harboring the NA gene H275Y variation was first identified in 2007, and was frequently identified worldwide in 2008â€"2009 [<a href="#CR17">17</a>]. However, since the 2009 A(H1N1)pdm09 pandemic, it occurred in <div class="â€‰1%_UNKNOWN" href="#CR18">
18, <a href="#CR19">19</a>]. Notably, such immunocompromised patients, when infected with influenza virus, could shed virus over a prolonged period, likely causing increased transmission. Moreover, as they shed drug-resistant virus while maintaining transmissibility, these patients may constitute a source for spreading drug-resistant influenza in the community [<a href="#CR18">18</a>].</div></p> <p id="Par31">Although NAI-resistant virus has been rarely observed since 2000, the KCDC, through the KINRESS, identified oseltamivir and peramivir-resistant A(H1N1)pdm09 viruses harboring the H275Y NA variation in patients with acute lymphoblastic leukemia and relapsed lymphoma hospitalized in the same general hospital, with both exhibiting prolonged virus excretion. Although there was no history of the two patients occupying the same ward, we were concerned about potential NAI-resistant virus transmission. The phylogenetic analysis showed that the two isolated A(H1N1)pdm09 viruses were genetically distinct. Moreover, there were no additional reports of similar viruses in that hospital. Furthermore, van der Vries et al. [<a href="#CR20">20</a>] demonstrated that A(H1N1)pdm09 virus-infected immunocompromised ferrets exhibited prolonged virus replication despite antiviral therapy, along with the H275Y substitution observed in the virus population from day 8 onwards only in ferrets that received oseltamivir. These results suggest that the H275Y substitution emerges rapidly in immunocompromised hosts under continuous antiviral selective pressure.</p> <p id="Par32">Mutations suspected to represent antigenic drift in immunocompromised patients were more likely to be observed in NA than HA, albeit at a very low frequency (around 1%). However, the NA mutations did not affect antigenic properties, besides drug resistance. Although the HA N158D substitution increases the binding affinity of H5N1 avian influenza virus and human receptor (Î±2â€"6-linked sialoside) [<a href="#CR21">21</a>], the function of the A/Korea/S0002/2019 HA A158E substitution functionality remains unknown (but it was not involved in antigenicity in this study). Alternatively, NA and HA had different mutation spectra in swine influenza viruses collected from April to June 2019 in the United States. The antigenic drift in immunocompromised patients may allow swine influenza virus insertion to occur without pig to human transmission, ultimately reducing the efficacy of influenza vaccine escape. Nevertheless, antisera from ferrets immunized with the influenza vaccine exhibited good inhibition of A/Korea/S0002/2019 and A/Korea/S0003/2019 infection.</p> </div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p id="Par33">The NA H275Y substitution and some HA or NA substitutions in drug-resistant A(H1N1)pdm09 viruses isolated from immunocompromised patients influence both antigenicity and NAI resistance. The viruses showed highly reduced inhibition, with over 100-fold increases in the IC<sub>50</sub> for oseltamivir and peramivir, but not zanamivir. Thus, zanamivir might be an option for immunocompromised patients when oseltamivir and peramivir are not effective. These findings also indicate the necessity of monitoring for NAI-resistant viruses in outpatients visiting clinics and in-patients, particularly for immunocompromised patients (e.g., with severe acute respiratory syndromes in general hospitals). Additionally, virus characterization can facilitate the risk assessment of NAI viruses.</p> </div> </div> <div class="back" title="back"> <div class="glossary" title="glossary"> <div class="title" tagx="title" title="title">
Abbreviations</div> <div class="def-list" title="def-list"> <div class="def-item" title="def-item"> <div class="term" title="term">
KINRESS</div> <div class="def" title="def"> <p id="Par5">Korea Influenza and Respiratory Viruses Surveillance System</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
SARI</div> <div class="def" title="def"> <p id="Par6">Severe Acute Respiratory Infection</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
H</div> <div class="def" title="def"> <p id="Par7">Histidine</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
Y</div> <div class="def" title="def"> <p id="Par8">Tyrosine</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
NAIs</div> <div class="def" title="def"> <p id="Par9">Neuraminidase inhibitors</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
NA</div> <div class="def" title="def"> <p id="Par10">Neuraminidase</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
HA</div> <div class="def" title="def"> <p id="Par11">Hemagglutinin</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
MDCK</div> <div class="def" title="def"> <p id="Par12">Madin-Darby canine kidney</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
GISAID</div> <div class="def" title="def"> <p id="Par13">Global Initiative on Sharing All Influenza Data</p> </div> </div> <div class="def-item" title="def-item"> <div class="term" title="term">
IC<sub>50</sub></div> <div class="def" title="def"> <p id="Par14">Half maximal inhibitory concentration</p> </div> </div> </div> </div> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p><b>Publisherâ€™s Note</b></p> <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p> </div> </div> <div class="ack" title="ack"> <p>We thank the national influenza surveillance participating institutes.</p> </div> <div class="title" tagx="title" title="title">
Authorsâ€™ contributions</div> <p>Conception and design: Chun Kang, Yoon-Seok Chung. Acquisition of data: Namjoo Lee, Mi-Seon Kim. Analysis and interpretation: Heui Man Kim, Yoon-Seok Chung. Writing, review and revision of the manuscript: Heui Man Kim. Study supervision: Chun Kang, Yoon-Seok Chung. All authors read and approved the final manuscript.</p> <div class="title" tagx="title" title="title">
Funding</div> <p>This study was supported by intramural funding from Korea Centers for Disease Control and Prevention (4834â€"303).</p> <div class="title" tagx="title" title="title">
Availability of data and materials</div> <p>The data supporting the conclusions of this article are included within the article.</p> <div class="title" tagx="title" title="title">
Ethics approval and consent to participate</div> <p id="Par34">All experimental procedures were approved by the institutional review boards of Korea Centers for Disease Control and Prevention (Ethics number: 2016-05-02-P-A).</p> <div class="title" tagx="title" title="title">
Consent for publication</div> <p id="Par35">Not applicable.</p> <div class="title" tagx="title" title="title">
Competing interests</div> <p id="Par36">The authors declare that they have no competing interests.</p> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CR1" /><span class="label" tagx="label" title="label">1.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cooper</span><span class="given-names" tagx="given-names" title="given-names">NJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sutton</span><span class="given-names" tagx="given-names" title="given-names">AJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abrams</span><span class="given-names" tagx="given-names" title="given-names">KR</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wailoo</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turner</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nicholson</span><span class="given-names" tagx="given-names" title="given-names">KG</span></span></span><span class="mixed-article-title" title="mixed-article-title">Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza a and B: systematic review and meta-analyses of randomized controlled trials</span><span class="source" tagx="source" title="source">BMJ.</span><span class="year" tagx="year" title="year">2003</span><span class="volume" tagx="volume" title="volume">326</span><span class="fpage" tagx="fpage" title="fpage">1235</span><span class="pub-id"><a href="https://dx.doi.org/10.1136/bmj.326.7401.1235">10.1136/bmj.326.7401.1235</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12791735">12791735</a></span></span></li> <li tag="ref"><a name="CR2" /><span class="label" tagx="label" title="label">2.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">McKimm-Breschkin</span><span class="given-names" tagx="given-names" title="given-names">JL</span></span></span><span class="mixed-article-title" title="mixed-article-title">Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance</span><span class="source" tagx="source" title="source">Influenza Other Respir Viruses</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">7</span><span class="fpage" tagx="fpage" title="fpage">25</span><span class="lpage" tagx="lpage" title="lpage">36</span><span class="pub-id"><a href="https://dx.doi.org/10.1111/irv.12047">10.1111/irv.12047</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23279894">23279894</a></span></span></li> <li tag="ref"><a name="CR3" /><span class="label" tagx="label" title="label">3.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heo</span><span class="given-names" tagx="given-names" title="given-names">YA</span></span></span><span class="mixed-article-title" title="mixed-article-title">Baloxavir: first global approval</span><span class="source" tagx="source" title="source">Drugs.</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">78</span><span class="fpage" tagx="fpage" title="fpage">693</span><span class="lpage" tagx="lpage" title="lpage">697</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s40265-018-0899-1">10.1007/s40265-018-0899-1</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29623652">29623652</a></span></span></li> <li tag="ref"><a name="CR4" /><span class="label" tagx="label" title="label">4.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moasser</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moasser</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zaraket</span><span class="given-names" tagx="given-names" title="given-names">H</span></span></span><span class="mixed-article-title" title="mixed-article-title">Incidence of antiviral drug resistance markers among human influenza a viruses in the eastern Mediterranean region, 2005-2016</span><span class="source" tagx="source" title="source">Infect Genet Evol</span><span class="year" tagx="year" title="year">2019</span><span class="volume" tagx="volume" title="volume">67</span><span class="fpage" tagx="fpage" title="fpage">60</span><span class="lpage" tagx="lpage" title="lpage">66</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.meegid.2018.10.023">10.1016/j.meegid.2018.10.023</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30389548">30389548</a></span></span></li> <li tag="ref"><a name="CR5" /><span class="label" tagx="label" title="label">5.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Redlberger-Fritz</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aberle</span><span class="given-names" tagx="given-names" title="given-names">SW</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Strassi</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Popow-Kraupp</span><span class="given-names" tagx="given-names" title="given-names">T</span></span></span><span class="mixed-article-title" title="mixed-article-title">Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus a (H1N1), a (H1N1) 2009, and a (H3N2) subtypes by melting point analysis</span><span class="source" tagx="source" title="source">Eur J Clin Microbiol Infect Dis</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">31</span><span class="fpage" tagx="fpage" title="fpage">1593</span><span class="lpage" tagx="lpage" title="lpage">1601</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s10096-011-1482-9">10.1007/s10096-011-1482-9</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22089329">22089329</a></span></span></li> <li tag="ref"><a name="CR6" /><span class="label" tagx="label" title="label">6.</span><span class="element-citation'"><span class="person-group'"><span class="collab'">collab: World Health Organization</span></span><span class="mixed-article-title" title="mixed-article-title">Summary table of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI)</span><span class="source" tagx="source" title="source">Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitors (NAI)</span><span class="year" tagx="year" title="year">2018</span></span></li> <li tag="ref"><a name="CR7" /><span class="label" tagx="label" title="label">7.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">A*STAR Bioinformatics Institute. FluSurver. <a href="http://flusurver.bii.a-star.edu.sg/">http://flusurver.bii.a-star.edu.sg/</a> Accessed 14 Mar 2016.</span></li> <li tag="ref"><a name="CR8" /><span class="label" tagx="label" title="label">8.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nguyen</span><span class="given-names" tagx="given-names" title="given-names">HT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fry</span><span class="given-names" tagx="given-names" title="given-names">AM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gubareva</span><span class="given-names" tagx="given-names" title="given-names">LV</span></span></span><span class="mixed-article-title" title="mixed-article-title">Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods</span><span class="source" tagx="source" title="source">Antivi Ther</span><span class="year" tagx="year" title="year">2012</span><span class="volume" tagx="volume" title="volume">17</span><span class="fpage" tagx="fpage" title="fpage">159</span><span class="lpage" tagx="lpage" title="lpage">173</span><span class="pub-id"><a href="https://dx.doi.org/10.3851/IMP2067">10.3851/IMP2067</a></span></span></li> <li tag="ref"><a name="CR9" /><span class="label" tagx="label" title="label">9.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Weinstock</span><span class="given-names" tagx="given-names" title="given-names">DM</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gubareva</span><span class="given-names" tagx="given-names" title="given-names">LV</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zuccotti</span><span class="given-names" tagx="given-names" title="given-names">G</span></span></span><span class="mixed-article-title" title="mixed-article-title">Prolonged shedding of multidrug-resistant influenza a virus in an immunocompromised patient</span><span class="source" tagx="source" title="source">New Engl J Med</span><span class="year" tagx="year" title="year">2003</span><span class="volume" tagx="volume" title="volume">348</span><span class="fpage" tagx="fpage" title="fpage">867</span><span class="lpage" tagx="lpage" title="lpage">868</span><span class="pub-id"><a href="https://dx.doi.org/10.1056/NEJM200302273480923">10.1056/NEJM200302273480923</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12606750">12606750</a></span></span></li> <li tag="ref"><a name="CR10" /><span class="label" tagx="label" title="label">10.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Choi</span><span class="given-names" tagx="given-names" title="given-names">JH</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">JY</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lee</span><span class="given-names" tagx="given-names" title="given-names">NJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwon</span><span class="given-names" tagx="given-names" title="given-names">D</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kang</span><span class="given-names" tagx="given-names" title="given-names">MG</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Development and evaluation of multiplex real-time RT-PCR assays for seasonal, pandemic a/H1pdm09 and avian a/H5 influenza viruses detection</span><span class="source" tagx="source" title="source">J Microbiol</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">51</span><span class="fpage" tagx="fpage" title="fpage">252</span><span class="lpage" tagx="lpage" title="lpage">257</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s12275-013-2452-y">10.1007/s12275-013-2452-y</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23625229">23625229</a></span></span></li> <li tag="ref"><a name="CR11" /><span class="label" tagx="label" title="label">11.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiao</span><span class="given-names" tagx="given-names" title="given-names">XY</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Su</span><span class="given-names" tagx="given-names" title="given-names">WZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jiang</span><span class="given-names" tagx="given-names" title="given-names">LZ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">X</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Susceptibility of influenza a (H1N1)/pdm2009, seasonal a (H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014</span><span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">7</span><span class="fpage" tagx="fpage" title="fpage">8488</span><span class="pub-id"><a href="https://dx.doi.org/10.1038/s41598-017-08282-6">10.1038/s41598-017-08282-6</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28814737">28814737</a></span></span></li> <li tag="ref"><a name="CR12" /><span class="label" tagx="label" title="label">12.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hoffmann</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stech</span><span class="given-names" tagx="given-names" title="given-names">J</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Guan</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Webster</span><span class="given-names" tagx="given-names" title="given-names">RG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Perez</span><span class="given-names" tagx="given-names" title="given-names">DR</span></span></span><span class="mixed-article-title" title="mixed-article-title">Universal primer set for the full-length amplification of all influenza a viruses</span><span class="source" tagx="source" title="source">Arch Virol</span><span class="year" tagx="year" title="year">2001</span><span class="volume" tagx="volume" title="volume">146</span><span class="fpage" tagx="fpage" title="fpage">2275</span><span class="lpage" tagx="lpage" title="lpage">2289</span><span class="pub-id"><a href="https://dx.doi.org/10.1007/s007050170002">10.1007/s007050170002</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11811679">11811679</a></span></span></li> <li tag="ref"><a name="CR13" /><span class="label" tagx="label" title="label">13.</span><span class="element-citation'"><span class="person-group'"><span class="collab'">collab: European Centre for Disease Prevention and Control</span></span><span class="source" tagx="source" title="source">Influenza virus characterization, Summary Europe, May 2019</span><span class="year" tagx="year" title="year">2019</span></span></li> <li tag="ref"><a name="CR14" /><span class="label" tagx="label" title="label">14.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lackenby</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Besselaar</span><span class="given-names" tagx="given-names" title="given-names">TG</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Daniels</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fry</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gregory</span><span class="given-names" tagx="given-names" title="given-names">V</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gubareva</span><span class="given-names" tagx="given-names" title="given-names">LV</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017</span><span class="source" tagx="source" title="source">Antivir Res</span><span class="year" tagx="year" title="year">2018</span><span class="volume" tagx="volume" title="volume">157</span><span class="fpage" tagx="fpage" title="fpage">38</span><span class="lpage" tagx="lpage" title="lpage">46</span><span class="pub-id"><a href="https://dx.doi.org/10.1016/j.antiviral.2018.07.001">10.1016/j.antiviral.2018.07.001</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29981793">29981793</a></span></span></li> <li tag="ref"><a name="CR15" /><span class="label" tagx="label" title="label">15.</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation">WHO GISRS Antiviral Susceptibility Expert Working Group. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016: World Health Organization; 2016.</span></li> <li tag="ref"><a name="CR16" /><span class="label" tagx="label" title="label">16.</span><span class="element-citation'"><span class="person-group'"><span class="collab'">collab: World Health Organization</span></span><span class="source" tagx="source" title="source">Manual for the laboratory diagnosis and virological surveillance of influenza</span><span class="year" tagx="year" title="year">2011</span></span></li> <li tag="ref"><a name="CR17" /><span class="label" tagx="label" title="label">17.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Okomo-Adhiambo</span><span class="given-names" tagx="given-names" title="given-names">M</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sleeman</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ballenger</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nguyen</span><span class="given-names" tagx="given-names" title="given-names">HT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mishin</span><span class="given-names" tagx="given-names" title="given-names">VP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sheu</span><span class="given-names" tagx="given-names" title="given-names">TG</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective</span><span class="source" tagx="source" title="source">Viruses.</span><span class="year" tagx="year" title="year">2010</span><span class="volume" tagx="volume" title="volume">2</span><span class="fpage" tagx="fpage" title="fpage">2269</span><span class="lpage" tagx="lpage" title="lpage">2289</span><span class="pub-id"><a href="https://dx.doi.org/10.3390/v2102269">10.3390/v2102269</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/21994620">21994620</a></span></span></li> <li tag="ref"><a name="CR18" /><span class="label" tagx="label" title="label">18.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Memoli</span><span class="given-names" tagx="given-names" title="given-names">MJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Athota</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reed</span><span class="given-names" tagx="given-names" title="given-names">S</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Czajkowski</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bristol</span><span class="given-names" tagx="given-names" title="given-names">T</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Proudfoot</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts</span><span class="source" tagx="source" title="source">Clin Infect Dis</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">58</span><span class="fpage" tagx="fpage" title="fpage">214</span><span class="lpage" tagx="lpage" title="lpage">224</span><span class="pub-id"><a href="https://dx.doi.org/10.1093/cid/cit725">10.1093/cid/cit725</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24186906">24186906</a></span></span></li> <li tag="ref"><a name="CR19" /><span class="label" tagx="label" title="label">19.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trebbien</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pedersen</span><span class="given-names" tagx="given-names" title="given-names">SS</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Vorborg</span><span class="given-names" tagx="given-names" title="given-names">K</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Franck</span><span class="given-names" tagx="given-names" title="given-names">KT</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fischer</span><span class="given-names" tagx="given-names" title="given-names">TK</span></span></span><span class="mixed-article-title" title="mixed-article-title">Development of oseltamivir and zanamivir resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014</span><span class="source" tagx="source" title="source">Euro Surveill</span><span class="year" tagx="year" title="year">2017</span><span class="volume" tagx="volume" title="volume">22</span><span class="fpage" tagx="fpage" title="fpage">30445</span><span class="pub-id"><a href="https://dx.doi.org/10.2807/1560-7917.ES.2017.22.3.30445">10.2807/1560-7917.ES.2017.22.3.30445</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28128091">28128091</a></span></span></li> <li tag="ref"><a name="CR20" /><span class="label" tagx="label" title="label">20.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van der Vries</span><span class="given-names" tagx="given-names" title="given-names">E</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stittelaar</span><span class="given-names" tagx="given-names" title="given-names">KJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">van Amerongen</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Veldhuis Kroeze</span><span class="given-names" tagx="given-names" title="given-names">EJ</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Waal</span><span class="given-names" tagx="given-names" title="given-names">L</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fraaij</span><span class="given-names" tagx="given-names" title="given-names">PL</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets</span><span class="source" tagx="source" title="source">PLoS Pathog</span><span class="year" tagx="year" title="year">2013</span><span class="volume" tagx="volume" title="volume">9</span><span class="fpage" tagx="fpage" title="fpage">e1003343</span><span class="pub-id"><a href="https://dx.doi.org/10.1371/journal.ppat.1003343">10.1371/journal.ppat.1003343</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23717200">23717200</a></span></span></li> <li tag="ref"><a name="CR21" /><span class="label" tagx="label" title="label">21.</span><span class="element-citation'"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">de Vries</span><span class="given-names" tagx="given-names" title="given-names">RP</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhu</span><span class="given-names" tagx="given-names" title="given-names">X</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">McBride</span><span class="given-names" tagx="given-names" title="given-names">R</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rigter</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hanson</span><span class="given-names" tagx="given-names" title="given-names">A</span></span><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhong</span><span class="given-names" tagx="given-names" title="given-names">G</span></span><span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Hemagglutinin receptor specificity and structural analyses of respiratory droplet-transmissible H5N1 viruses</span><span class="source" tagx="source" title="source">J Virol</span><span class="year" tagx="year" title="year">2014</span><span class="volume" tagx="volume" title="volume">88</span><span class="fpage" tagx="fpage" title="fpage">768</span><span class="lpage" tagx="lpage" title="lpage">773</span><span class="pub-id"><a href="https://dx.doi.org/10.1128/JVI.02690-13">10.1128/JVI.02690-13</a></span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24173215">24173215</a></span></span></li> </ul> </div> </div>  </body></html>